KDR and cancer: We are currently entering the third era of mRCC therapy with the challenging aim of combining immune–immune and immune–VEGFR-TKI, which is a direct portrait of the peculiar underlying pathophysiology of disease, being dependent on angiogenesis and the close connection between cancer cells and the immune system.